Should the two-trial paradigm still be the gold standard in drug assessment? (2023)
Attributed to:
Innovative statistical methods for clinical trial pathways supporting regulatory drug approval
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/pst.2262
PubMed Identifier: 36054079
Publication URI: http://europepmc.org/abstract/MED/36054079
Type: Journal Article/Review
Volume: 22
Parent Publication: Pharmaceutical statistics
Issue: 1
ISSN: 1539-1604